Breast cancer-specific survival | Overall survival | |||||||
---|---|---|---|---|---|---|---|---|
Factor | Event/at risk | HR | 95% CI | P | Event/at risk | HR | 95% CI | P |
Tumor size | ||||||||
pT1 | 7/44 | 1 | 11/44 | 1 | ||||
pT2 | 9/42 | 1.47 | 0.55–3.96 | 0.439 | 16/42 | 1.70 | 0.79–3.67 | 0.169 |
Node status | ||||||||
pN0 | 4/33 | 1 | 9/33 | 1 | ||||
pN+ | 12/52 | 2.00 | 0.64 –6.19 | 0.222 | 18/52 | 1.33 | 0.60–2.96 | 0.484 |
Histological grade | ||||||||
1 | 3/16 | 1 | 6/16 | 1 | ||||
2 | 10/57 | 0.94 | 0.26–3.42 | 0.924 | 16/57 | 0.76 | 0.30–1.94 | 0.564 |
3 | 3/11 | 1.48 | 0.30–7.35 | 0.631 | 5/11 | 1.30 | 0.40–4.28 | 0.661 |
Histological grade | ||||||||
1 + 2 | 13/73 | 1 | 22/73 | 1 | ||||
3 | 3/11 | 1.56 | 0.44–5.46 | 0.335 | 5/11 | 1.61 | 0.61–4.25 | 0.335 |
Age | ||||||||
< 55 years | 7/35 | 1 | 7/35 | 1 | ||||
≥ 55 years | 9/51 | 0.93 | 0.35–2.51 | 0.890 | 20/51 | 2.09 | 0.89–4.95 | 0.085 |
ER | ||||||||
≥ 10% | 15/75 | 1 | 26/75 | 1 | ||||
< 10% | 1/7 | 0.63 | 0.08–4.73 | 0.646 | 1/7 | 0.36 | 0.05–2.65 | 0.294 |
PR | ||||||||
≥ 10% | 11/55 | 1 | 17/55 | 1 | ||||
< 10% | 4/27 | 0.72 | 0.23–2.25 | 0.566 | 9/27 | 0.98 | 0.43–2.19 | 0.951 |
Chemotherapy* | ||||||||
Yes | 6/30 | 1 | 6/30 | 1 | ||||
No | 10/56 | 0.93 | 0.34–2.57 | 0.893 | 21/56 | 1.97 | 0.80–4.89 | 0.135 |
AAS | ||||||||
> 16.7 | 13/79 | 1 | 21/79 | 1 | ||||
≤ 16.7 | 3/7 | 3.81 | 1.07–13.56 | 0.026 | 6/7 | 5.37 | 2.14–13.51 | < 0.001 |
Z-4OHtam | ||||||||
> 3.26 nM | 12/76 | 1 | 20/76 | 1 | ||||
≤ 3.26 nM | 4/10 | 3.56 | 1.14–11.11 | 0.020 | 7/10 | 4.05 | 1.70–9.64 | 0.001 |
Z-endoxifen | ||||||||
> 9.00 nM | 13/79 | 1 | 22/79 | 1 | ||||
≤ 9.00 nM | 3/7 | 3.73 | 1.05–13.23 | 0.029 | 5/7 | 4.03 | 1.51–10.74 | 0.003 |